Francesca Magrinelli

List of Publications by Year
in descending order

56 papers	839 citations	706676 14 h-index	620720 26 g-index
56 all docs	56 docs citations	56 times ranked	1441 citing authors

#	Article	IF	Citations
1	Dissecting the Phenotype and Genotype of <scp>PLA2G6</scp>â€Related Parkinsonism. Movement Disorders, 2022, 37, 148-161.	2.2	32
2	Heterozygous <scp>EIF2AK2</scp> Variant Causes Adolescenceâ€Onset Generalized Dystonia Partially Responsive to <scp>DBS</scp>. Movement Disorders Clinical Practice, 2022, 9, 268-271.	0.8	7
3	Early downregulation of hsa-miR-144-3p in serum from drug-naÃ¯ve Parkinsonâ€™s disease patients. Scientific Reports, 2022, 12, 1330.	1.6	14
4	Biallelic Lossâ€ofâ€Function NDUFA12 Variants Cause a Wide Phenotypic Spectrum from Leigh/Leighâ€Like Syndrome to Isolated Optic Atrophy. Movement Disorders Clinical Practice, 2022, 9, 218-228.	0.8	5
5	Restless Legs Syndrome: Known Knowns and Known Unknowns. Brain Sciences, 2022, 12, 118.	1.1	13
6	Reply to: Juvenile PLA2G6â€parkinsonism due to Indian â€˜Asianâ€™ p.R741Q mutation, and response to STN DBS. Movement Disorders, 2022, 37, 658-662.	2.2	5
7	Relationship between risk and protective factors and clinical features of Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 80-85.	1.1	12
8	Biallelic variants in <scp>ZNF142</scp> lead to a syndromic neurodevelopmental disorder. Clinical Genetics, 2022, 102, 98-109.	1.0	6
9	Lateâ€Onset Chorea in JAK2 â€Associated Essential Thrombocythemia. Movement Disorders Clinical Practice, 2021, 8, 145-148.	0.8	5
10	Huntington disease-like phenotype in a patient with ANO3 mutation. Parkinsonism and Related Disorders, 2021, 90, 120-122.	1.1	5
11	Throatâ€Clearing Vocalizations in Primary Brain Calcification Syndromes. Movement Disorders Clinical Practice, 2021, 8, 627-630.	0.8	1
12	Expanding the Spectrum of Movement Disorders Associated With C9orf72 Hexanucleotide Expansions. Neurology: Genetics, 2021, 7, e575.	0.9	20
13	Challenges in Clinicogenetic Correlations: One Gene â€“ Many Phenotypes. Movement Disorders Clinical Practice, 2021, 8, 299-310.	0.8	34
14	Paroxysmal, exercise-induced, diurnally fluctuating dystonia: Expanding the phenotype of SPG8. Parkinsonism and Related Disorders, 2021, 85, 26-28.	1.1	3
15	Movement Disorders and Liver Disease. Movement Disorders Clinical Practice, 2021, 8, 828-842.	0.8	7
16	Xâ€Linked Parkinsonism: Phenotypic and Genetic Heterogeneity. Movement Disorders, 2021, 36, 1511-1525.	2.2	10
17	RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain, 2021, 144, 1542-1550.	3.7	63
18	Childhoodâ€Onset Chorea Caused by a Recurrent De Novo DRD2 Variant. Movement Disorders, 2021, 36, 1472-1473.	2.2	6

#	Article	IF	Citations
19	A 58â€yearâ€old man with Bâ€cell chronic lymphocytic leukemia and multiple strokes. Brain Pathology, 2021, 31, e13004.	2.1	0
20	Ciliary Dysfunction: The Hairy Explanation of Normal Pressure Hydrocephalus?. Movement Disorders Clinical Practice, 2020, 7, 30-31.	0.8	1
21	Reply: Pentameric repeat expansions: cortical myoclonus or cortical tremor? and Cortical tremor: a tantalizing conundrum between cortex and cerebellum. Brain, 2020, 143, e88-e88.	3.7	1
22	Voxel-based morphometry and task functional magnetic resonance imaging in essential tremor: evidence for a disrupted brain network. Scientific Reports, 2020, 10, 15061.	1.6	11
23	The Need to Tic. Movement Disorders Clinical Practice, 2020, 7, 863-864.	0.8	1
24	A new family with GLRB-related hyperekplexia showing chorea in homo- and heterozygous variant carriers. Parkinsonism and Related Disorders, 2020, 79, 97-99.	1.1	4
25	Psychiatric Manifestations of <scp>ATP13A2</scp> Mutations. Movement Disorders Clinical Practice, 2020, 7, 838-841.	0.8	6
26	Criss-cross gait. Neurology, 2020, 95, 500-501.	1.5	5
27	Toward an Early Realâ€Time Quakingâ€Induced Conversionâ€“Based Diagnostic Biomarker for Lewy Bodyâ€“Related Synucleinopathies. Movement Disorders Clinical Practice, 2020, 7, 780-781.	0.8	0
28	Risk factors of Parkinson disease. Neurology, 2020, 95, e2500-e2508.	1.5	41
29	Unravelling the enigma of cortical tremor and other forms of cortical myoclonus. Brain, 2020, 143, 2653-2663.	3.7	38
30	Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria. Parkinsonism and Related Disorders, 2020, 77, 121-140.	1.1	13
31	Huntington disease like 2 (HDL-2) with parkinsonism and abnormal DAT-SPECT â€“ A novel observation. Parkinsonism and Related Disorders, 2020, 71, 46-48.	1.1	4
32	Upper camptocormia in Parkinson's disease: Neurophysiological and imaging findings of both central and peripheral pathophysiological mechanisms. Parkinsonism and Related Disorders, 2020, 71, 28-34.	1.1	6
33	Pharmacological treatment for familial amyloid polyneuropathy. The Cochrane Library, 2020, 4, CD012395.	1.5	8
34	Four-week trunk-specific exercise program decreases forward trunk flexion in Parkinson's disease: A single-blinded, randomized controlled trial. Parkinsonism and Related Disorders, 2019, 64, 268-274.	1.1	38
35	Twelveâ€year Followâ€up of A Large Italian Family with Atypical Phenotypes of DYT1â€dystonia. Movement Disorders Clinical Practice, 2019, 6, 166-170.	0.8	6
36	The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study. Clinical Neurophysiology, 2018, 129, 21-32.	0.7	21

#	Article	IF	Citations
37	Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients. Journal of Neurology, 2018, 265, 1676-1683.	1.8	17
38	Diagnostic methods and emerging treatments for adult neuronal ceroid lipofuscinoses (Kufs disease). Expert Opinion on Orphan Drugs, 2017, 5, 487-501.	0.5	2
39	Teaching Video Neuro Images : Bent spine syndrome as an early presentation of late-onset Pompe disease. Neurology, 2017, 89, e21-e22.	1.5	2
40	The Italian Consensus Conference on Pain in Neurorehabilitation: rationale and methodology. Journal of Pain Research, 2016, 9, 311.	0.8	14
41	Pathophysiology of Motor Dysfunction in Parkinsonâ€™s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson's Disease, 2016, 2016, 1-18.	0.6	161
42	Diagnosing and assessing pain in neurorehabilitation: from translational research to the clinical setting. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 717-729.	1.1	4
43	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	1.1	14
44	The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy. Journal of Diabetes Research, 2015, 2015, 1-7.	1.0	47
45	Effect of 5% Lidocaine Medicated Plaster on Pain Intensity and Paroxysms in Classical Trigeminal Neuralgia. Annals of Pharmacotherapy, 2014, 48, 1521-1524.	0.9	10
46	Diagnostic and Therapeutic Pitfalls in Considering Chronic Pain as a Disease. Pain Medicine, 2014, 15, 1640-1642.	0.9	2
47	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	0.9	22
48	Longâ€Term Response of Neuropathic Pain to Intravenous Immunoglobulin in Relapsing Diabetic Lumbosacral Radiculoplexus Neuropathy. A Case Report. Pain Practice, 2014, 14, E85-90.	0.9	10
49	Periodic thigh pain from radicular endometriosis. Practical Neurology, 2014, 14, 351-353.	0.5	2
50	Letter to the Editor. Pain, 2014, 155, 201-202.	2.0	0
51	Neuropathic pain: diagnosis and treatment. Practical Neurology, 2013, 13, 292-307.	0.5	76
52	No evidence of a neuropathic origin in hemiplegic shoulder pain. Pain, 2013, 154, 958-959.	2.0	2
53	Pharmacological treatment for familial amyloid neuropathy. The Cochrane Library, 0, , .	1.5	1
54	Abnormal <scp>DaTscan</scp> in <scp>GM1</scp> â€gangliosidosis type <scp>III</scp> manifesting with dystoniaâ€parkinsonism. Movement Disorders Clinical Practice, 0, , .	0.8	0

#	Article	IF	Citations
55	PRKRAP1 and Other Pseudogenes in Movement Disorders: The Troublemakers in Genetic Analyses Are More Than Genomic Fossils. Movement Disorders Clinical Practice, 0, , .	0.8	0
56	Breakthrough News in Adenoviral Vectorâ€Mediated <scp>AADC</scp> Gene Therapy: Lessons from the Success in <scp>AADC</scp> Deficiency and Possible Future Applications. Movement Disorders Clinical Practice, 0, , .	0.8	1